The pharmaceutical giant is slashing 11% of its workforce as it continues to lose market share. Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to encroach on its market share.

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli Lilly’s blockbuster weight-loss drug.

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with Zepbound-topping data in another key assessment.

CVS Caremark is facing multiple federal lawsuits by patients challenging its decision to remove weight-loss drug Zepbound from its list of preferred medications after signing a rebate agreement with Wegovy maker Novo Nordisk A/S.

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (semaglutide) 2.

Novo Nordisk (NVO) stock in focus as its obesity drug Wegovy outperforms Eli Lilly's (LLY) rival Zepbound in reducing serious heart issues by over 50%. Read more here.